EGFR and adenocarcinoma: In a French study by Vallee et al., one of the largest studies in Europe, [28] 1403 tumor samples were analyzed, of which 1144 were adenocarcinomas and 101 were NSCLC-NOS; EGFR mutations were found in 14.7 % and 4.0 %, of adenocarcinomas and NSCLC-NOS, respectively.